{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T06:29:56Z","timestamp":1776752996378,"version":"3.51.2"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007950","name":"Tanta University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.lfs.2021.119849","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T01:54:23Z","timestamp":1627696463000},"page":"119849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Novel in vivo potential of trifluoperazine to ameliorate doxorubicin-induced cardiotoxicity involves suppression of NF-\u03baB and apoptosis"],"prefix":"10.1016","volume":"283","author":[{"given":"Ahmed E.","family":"Goda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr M.","family":"Elenany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa E.","family":"Elsisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.lfs.2021.119849_bb0005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/mol.119.115725","article-title":"Insights into doxorubicin-induced cardiotoxicity: molecular mechanisms, preventive strategies, and early monitoring","volume":"96","author":"Wenningmann","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119849_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101394","article-title":"Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: have we been barking up the wrong tree?","volume":"29","author":"Kalyanaraman","year":"2020","journal-title":"Redox Biol."},{"issue":"5","key":"10.1016\/j.lfs.2021.119849_bb0015","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1016\/j.carpath.2009.06.006","article-title":"Respiratory chain deficiency precedes the disrupted calcium homeostasis in chronic doxorubicin cardiomyopathy","volume":"19","author":"Lebrecht","year":"2010","journal-title":"Cardiovasc. Pathol."},{"issue":"4","key":"10.1016\/j.lfs.2021.119849_bb0020","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/mol.114.093849","article-title":"Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A","volume":"86","author":"Hanna","year":"2014","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2021.119849_bb0025","doi-asserted-by":"crossref","first-page":"9850","DOI":"10.1038\/s41598-019-46367-6","article-title":"Blockade of L-type Ca[2) channel attenuates doxorubicin-induced cardiomyopathy via suppression of CaMKII-NF-kappaB pathway","volume":"9","author":"Ikeda","year":"2019","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.lfs.2021.119849_bb0030","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/BF02256119","article-title":"Calcium overload and cardiac function","volume":"11","author":"Vassalle","year":"2004","journal-title":"J. Biomed. Sci."},{"issue":"2","key":"10.1016\/j.lfs.2021.119849_bb0035","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/cvr\/cvs116","article-title":"Calcium-mediated cell death during myocardial reperfusion","volume":"94","author":"Garcia-Dorado","year":"2012","journal-title":"Cardiovasc. Res."},{"issue":"21","key":"10.1016\/j.lfs.2021.119849_bb0040","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1111\/febs.12337","article-title":"Calmodulin in a heartbeat","volume":"280","author":"Sorensen","year":"2013","journal-title":"FEBS J."},{"issue":"2","key":"10.1016\/j.lfs.2021.119849_bb0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.cmet.2015.01.005","article-title":"Altered myocardial calcium cycling and energetics in heart failure\u2013a rational approach for disease treatment","volume":"21","author":"Gorski","year":"2015","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.lfs.2021.119849_bb0050","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm.4017","article-title":"CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis","volume":"22","author":"Zhang","year":"2016","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.lfs.2021.119849_bb0055","doi-asserted-by":"crossref","first-page":"10492","DOI":"10.1038\/s41598-017-10673-8","article-title":"Mitochondrial permeability transition pore: sensitivity to opening and mechanistic dependence on substrate availability","volume":"7","author":"Briston","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.lfs.2021.119849_bb0060","article-title":"Trifluoperazine for schizophrenia. Cochrane Database Syst","volume":"2004","author":"Marques","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.lfs.2021.119849_bb0065","first-page":"CD007786","article-title":"Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood","volume":"2","author":"Phillips","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.lfs.2021.119849_bb0070","first-page":"3300","article-title":"Trifluoperazine prevents FOXO1 nuclear excretion and reverses doxorubicin-resistance in the SHG44\/DOX drug-resistant glioma cell line","volume":"42","author":"Chen","year":"2018","journal-title":"Int. J. Mol. Med."},{"issue":"13","key":"10.1016\/j.lfs.2021.119849_bb0075","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.3390\/ijms20133218","article-title":"Trifluoperazine, an antipsychotic drug, effectively reduces drug resistance in cisplatin-resistant urothelial carcinoma cells via suppressing bcl-xL: an in vitro and in vivo study","volume":"20","author":"Kuo","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.lfs.2021.119849_bb0080","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/mol.114.096941","article-title":"Repurposing the antipsychotic trifluoperazine as an antimetastasis agent","volume":"87","author":"Pulkoski-Gross","year":"2015","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.lfs.2021.119849_bb0085","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1080\/10245332.2017.1396045","article-title":"Involvement of oncogenic tyrosine kinase NPM-ALK in trifluoperazine-induced cell cycle arrest and apoptosis in ALK anaplastic large cell lymphoma","volume":"23","author":"Hu","year":"2018","journal-title":"Hematology"},{"issue":"12","key":"10.1016\/j.lfs.2021.119849_bb0090","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3390\/cancers11121869","article-title":"Dissecting the anticancer mechanism of trifluoperazine on pancreatic ductal adenocarcinoma","volume":"11","author":"Huang","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lfs.2021.119849_bb0095","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3389\/fphar.2019.01029","article-title":"Antipsychotic drug trifluoperazine suppresses colorectal cancer by inducing G0\/G1 arrest and apoptosis","volume":"10","author":"Xia","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119849_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105295","article-title":"Repurposing of antipsychotic trifluoperazine for treating brain metastasis, lung metastasis and bone metastasis of melanoma by disrupting autophagy flux","volume":"163","author":"Xia","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.lfs.2021.119849_bb0105","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nsb1194-795","article-title":"Trifluoperazine-induced conformational change in Ca(2)-calmodulin","volume":"1","author":"Vandonselaar","year":"1994","journal-title":"Nat. Struct. Biol."},{"issue":"51","key":"10.1016\/j.lfs.2021.119849_bb0110","doi-asserted-by":"crossref","first-page":"15259","DOI":"10.1021\/bi00255a006","article-title":"Drug binding by calmodulin: crystal structure of a calmodulin-trifluoperazine complex","volume":"33","author":"Cook","year":"1994","journal-title":"Biochemistry"},{"issue":"1\u20132","key":"10.1016\/j.lfs.2021.119849_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2005.11.050","article-title":"Trifluoperazine, an orally available clinically used drug, disrupts opioid antinociceptive tolerance","volume":"397","author":"Tang","year":"2006","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.lfs.2021.119849_bb0120","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/jpet.107.132167","article-title":"Reversal of chronic inflammatory pain by acute inhibition of Ca2 \/calmodulin-dependent protein kinase II","volume":"325","author":"Luo","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.lfs.2021.119849_bb0125","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1124\/jpet.109.152165","article-title":"Acute inhibition of Ca2 \/calmodulin-dependent protein kinase II reverses experimental neuropathic pain in mice","volume":"330","author":"Chen","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"17","key":"10.1016\/j.lfs.2021.119849_bb0130","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1161\/CIRCULATIONAHA.115.017443","article-title":"Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification","volume":"133","author":"Li","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2021.119849_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115185","article-title":"Enhanced in vivo targeting of estrogen receptor alpha signaling in murine mammary adenocarcinoma by nilotinib\/rosuvastatin novel combination","volume":"404","author":"Goda","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2021.119849_bb0140","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1038\/s41598-018-23669-9","article-title":"Subcutaneous ehrlich ascites carcinoma mice model for studying cancer-induced cardiomyopathy","volume":"8","author":"Mishra","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.lfs.2021.119849_bb0145","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1038\/s41467-018-05613-7","article-title":"A selective inhibitor of ceramide synthase 1 reveals a novel role in fat metabolism","volume":"9","author":"Turner","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2021.119849_bb0150","series-title":"Histotechnology: A Self-instructional Text","first-page":"131","article-title":"Connective and muscle tissue","author":"Carson","year":"2007"},{"issue":"5","key":"10.1016\/j.lfs.2021.119849_bb0155","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jacc.2010.04.019","article-title":"Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart","volume":"56","author":"Drakos","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.lfs.2021.119849_bb0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2044-5040-1-17","article-title":"Caspase-3, myogenic transcription factors and cell cycle inhibitors are regulated by leukemia inhibitory factor to mediate inhibition of myogenic differentiation","volume":"1","author":"Hunt","year":"2011","journal-title":"Skelet. Muscle"},{"issue":"4","key":"10.1016\/j.lfs.2021.119849_bb0165","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1172\/JCI110328","article-title":"Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine","volume":"68","author":"Doroshow","year":"1981","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.lfs.2021.119849_bb0170","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/obr.12934","article-title":"Effects of antidepressant and antipsychotic use on weight gain: a systematic review","volume":"20","author":"Alonso-Pedrero","year":"2019","journal-title":"Obes. Rev."},{"issue":"18","key":"10.1016\/j.lfs.2021.119849_bb0175","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/heartjnl-2020-317604","article-title":"What is 'normal' left ventricular ejection fraction?","volume":"106","author":"Hudson","year":"2020","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.lfs.2021.119849_bb0180","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/bja\/aet118","article-title":"Non-invasive method for rapid bedside estimation of inotropy: theory and preliminary clinical validation","volume":"111","author":"Smith","year":"2013","journal-title":"Br. J. Anaesth."},{"issue":"9","key":"10.1016\/j.lfs.2021.119849_bb0185","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1253\/circj.CJ-13-0627","article-title":"Biochemical and physiological regulation of cardiac myocyte contraction by cardiac-specific myosin light chain kinase","volume":"77","author":"Tsukamoto","year":"2013","journal-title":"Circ. J."},{"issue":"52","key":"10.1016\/j.lfs.2021.119849_bb0190","doi-asserted-by":"crossref","first-page":"40819","DOI":"10.1074\/jbc.M110.160499","article-title":"Cardiac myosin light chain kinase is necessary for myosin regulatory light chain phosphorylation and cardiac performance in vivo","volume":"285","author":"Ding","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"3\u20134","key":"10.1016\/j.lfs.2021.119849_bb0195","first-page":"195","article-title":"Differential effects of doxorubicin on atrial natriuretic peptide expression in vivo and in vitro","volume":"34","author":"Rahman","year":"2001","journal-title":"Biol. Res."},{"issue":"1","key":"10.1016\/j.lfs.2021.119849_bb0200","doi-asserted-by":"crossref","first-page":"62","DOI":"10.15420\/cfr.2017:3:2","article-title":"Cardiac atrophy and heart failure in cancer","volume":"3","author":"Sweeney","year":"2017","journal-title":"Card. Fail. Rev."},{"issue":"9","key":"10.1016\/j.lfs.2021.119849_bb0205","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1161\/CIRCRESAHA.110.226928","article-title":"Multiple facets of NF-?B in the heart: to be or not to NF-?B","volume":"108","author":"Gordon","year":"2011","journal-title":"Circ. Res."},{"issue":"7","key":"10.1016\/j.lfs.2021.119849_bb0210","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3390\/ijms20071599","article-title":"NFkappaB is a key player in the crosstalk between inflammation and cardiovascular diseases","volume":"20","author":"Fiordelisi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.lfs.2021.119849_bb0215","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/hdi.12196","article-title":"Nephrotic syndrome and acute renal failure during pegylated liposomal doxorubicin treatment","volume":"18","author":"Carron","year":"2014","journal-title":"Hemodial. Int."},{"key":"10.1016\/j.lfs.2021.119849_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117599","article-title":"New molecular and biochemical insights of doxorubicin-induced hepatotoxicity","volume":"250","author":"Prasanna","year":"2020","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.lfs.2021.119849_bb0225","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bbrc.2004.12.002","article-title":"CaMKII activates ASK1 and NF-kappaB to induce cardiomyocyte hypertrophy","volume":"327","author":"Kashiwase","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.lfs.2021.119849_bb0230","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.yjmcc.2006.07.006","article-title":"Regulating the regulator: NF-kappaB signaling in heart","volume":"41","author":"Hall","year":"2006","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"7423","key":"10.1016\/j.lfs.2021.119849_bb0235","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nature11444","article-title":"CaMKII determines mitochondrial stress responses in heart","volume":"491","author":"Joiner","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119849_bb0240","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.yjmcc.2014.09.023","article-title":"The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection","volume":"78","author":"Bernardi","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"2","key":"10.1016\/j.lfs.2021.119849_bb0245","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.taap.2012.12.003","article-title":"Doxorubicin induced myocardial injury is exacerbated following ischaemic stress via opening of the mitochondrial permeability transition pore","volume":"268","author":"Gharanei","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.lfs.2021.119849_bb0250","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.20032053","article-title":"Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology","volume":"200","author":"Stavrovskaya","year":"2004","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.lfs.2021.119849_bb0255","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1073\/pnas.0409402102","article-title":"Disturbed Ca2 signaling and apoptosis of medium spiny neurons in Huntington's disease","volume":"102","author":"Tang","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2021.119849_bb0260","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCHEARTFAILURE.114.001180","article-title":"Sexual dimorphism of doxorubicin-mediated cardiotoxicity: potential role of energy metabolism remodeling","volume":"8","author":"Moulin","year":"2015","journal-title":"Circ. Heart Fail."},{"issue":"9","key":"10.1016\/j.lfs.2021.119849_bb0265","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00204-014-1219-5","article-title":"The Ca2 -calmodulin-Ca2 \/calmodulin-dependent protein kinase II signaling pathway is involved in oxidative stress-induced mitochondrial permeability transition and apoptosis in isolated rat hepatocytes","volume":"88","author":"Toledo","year":"2014","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.lfs.2021.119849_bb0270","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3389\/fphys.2020.00735","article-title":"An overview of the role of calcium\/calmodulin-dependent protein kinase in cardiorenal syndrome","volume":"11","author":"Junho","year":"2020","journal-title":"Front. Physiol."},{"issue":"12","key":"10.1016\/j.lfs.2021.119849_bb0275","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1161\/01.STR.28.12.2539","article-title":"The calmodulin antagonist trifluoperazine in transient focal brain ischemia in rats.\u00a0Anti-ischemic effect and therapeutic window","volume":"28","author":"Kuroda","year":"1997","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.lfs.2021.119849_bb0280","first-page":"H1821","article-title":"Intracellular calcium dynamics in mouse model of myocardial stunning","volume":"274","author":"Hampton","year":"1998","journal-title":"Am. J. Phys."},{"issue":"2","key":"10.1016\/j.lfs.2021.119849_bb0285","first-page":"99","article-title":"Role of allopurinol, verapamil, dexamethasone and trifluoperazine as prophylactic agents in intestinal ischemia-reperfusion","volume":"30","author":"Devec\u00ed","year":"2008","journal-title":"Anal. Quant. Cytol. Histol."},{"issue":"1","key":"10.1016\/j.lfs.2021.119849_bb0290","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13046-017-0588-z","article-title":"Trifluoperazine, a novel autophagy inhibitor, increases radiosensitivity in glioblastoma by impairing homologous recombination","volume":"36","author":"Zhang","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.lfs.2021.119849_bb0295","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1164\/rccm.201207-1180OC","article-title":"Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer","volume":"186","author":"Yeh","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lfs.2021.119849_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111058","article-title":"Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells","volume":"133","author":"Datta","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.lfs.2021.119849_bb0305","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0163-7258(89)90066-1","article-title":"The uses and limitations of calmodulin antagonists","volume":"44","author":"Veigl","year":"1989","journal-title":"Pharmacol. Ther."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521008365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521008365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:49:47Z","timestamp":1758401387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320521008365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":61,"alternative-id":["S0024320521008365"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119849","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel in vivo potential of trifluoperazine to ameliorate doxorubicin-induced cardiotoxicity involves suppression of NF-\u03baB and apoptosis","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119849","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"119849"}}